Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seagen Inc.    SGEN

SEAGEN INC.

(SGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
198.22(c) 198.02(c) 197.71(c) 200.66(c) 196.92(c) Last
698 890 444 469 402 896 617 372 479 621 Volume
-1.35% -0.10% -0.16% +1.49% -1.86% Change
More quotes
Financials (USD)
Sales 2020 1 502 M - -
Net income 2020 -47,9 M - -
Net cash position 2020 1 493 M - -
P/E ratio 2020 -321x
Yield 2020 -
Sales 2021 1 824 M - -
Net income 2021 15,7 M - -
Net cash position 2021 1 548 M - -
P/E ratio 2021 1 634x
Yield 2021 -
Capitalization 34 263 M 34 263 M -
EV / Sales 2020 21,8x
EV / Sales 2021 17,9x
Nbr of Employees 1 605
Free-Float 99,3%
More Financials
Company
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV... 
More about the company
Notations Surperformance© of Seagen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SEAGEN INC.
10/20SEAGEN INC. : Regulation FD Disclosure (form 8-K)
AQ
10/14SEAGEN : to Host Conference Call and Webcast Discussion of Third Quarter 2020 Fi..
AQ
10/13ASTELLAS PHARMA : and Seagen Announce Positive Topline Results from Second Cohor..
AQ
10/13SEAGEN : to Host Conference Call and Webcast Discussion of Third Quarter 2020 Fi..
BU
10/13SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/12SEATTLE GENETICS : Astellas and Seagen Announce Positive Topline Results from Se..
PR
10/12SEATTLE GENETICS : Seagen and Astellas Announce Positive Topline Results from Se..
BU
10/09SEATTLE GENETICS : Announces Corporate Name Change to Seagen Inc.
AQ
10/08SEATTLE GENETICS INC /WA : Amendments to Articles of Inc. or Bylaws; Change in F..
AQ
10/08SEATTLE GENETICS : Announces Corporate Name Change to Seagen Inc.
BU
09/24ASTELLAS PHARMA : and Seattle Genetics Announce PADCEV Significantly Improved Ov..
AQ
09/21SEATTLE GENETICS : and Genmab Present Data from Tisotumab Vedotin innovaTV 204 P..
BU
09/18SEATTLE GENETICS INC /WA : Other Events, Financial Statements and Exhibits (form..
AQ
09/18SEATTLE GENETICS : and Astellas Announce PADCEVģ (enfortumab vedotin-ejfv) Signi..
BU
09/15SEATTLE GENETICS : and Merck Announce Two Strategic Oncology Collaborations
AQ
More news
News in other languages on SEAGEN INC.
03:45aSEAGEN INC. : Veröffentlichung des Quartalsergebnisses
03:45aSEAGEN INC. : publication des résultats trimestriels
10/1410 Biotechs qui font parler d'elles
09/14Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt
09/14Aktien New York: Übernahme-Welle sorgt für einen starken Wochenauftakt
More news
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 195,59 $
Last Close Price 196,92 $
Spread / Highest target 29,0%
Spread / Average Target -0,68%
Spread / Lowest Target -29,9%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEAGEN INC.72.54%34 263
LONZA GROUP AG62.80%47 152
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
MODERNA, INC.260.58%27 830
IMMUNOMEDICS, INC.315.22%20 324